Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
NCT00457860
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Leukemia
Interventions
DRUG:
Immunotoxin therapy
DRUG:
CAT-8015 immunotoxin
PROCEDURE:
Biological therapy
Sponsor
Cambridge Antibody Technology